Microdosing

<p>Microdosing, or micro-dosing, involves the administration of sub-therapeutic doses of <a href="/facts/Drug/FFFUI9n4">drugs</a> to study their effects in humans, aiming to gather preliminary data on safety, <a href="/facts/Pharmacokinetic/x4CUUnle">pharmacokinetics</a>, and potential therapeutic benefits without producing significant physiological effects.  This is called a "<a href="/facts/Phase_0/o8hEodVu">Phase 0</a> study" and is usually conducted before clinical <a href="/facts/Phases_of_clinical_research/o8hEodVu">Phase I</a> to predict whether a drug is viable for the next phase of testing. Human microdosing aims to reduce the resources spent on non-viable drugs and the amount of testing done on animals. 
</p><p>Less commonly, the term "microdosing" is also sometimes used to refer to precise dispensing of small amounts of a drug substance (e.g., a powder API) for a drug product (e.g., a capsule) and, when the drug substance also happens to be liquid, this can potentially overlap what is termed <a href="/facts/Microdispensing/utAqzE57">microdispensing</a>. For example, <a href="/facts/Psychedelic_microdosing/vusLgJ8R">psychedelic microdosing</a>.
</p>

Microdosing open-in-new

Microdosing